At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 264 enrolled
Drug / intervention
nemolizumab (CIM331) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL THERAPY
In Brief
A Phase 2 clinical trial evaluating nemolizumab (CIM331) and Placebo for Atopic Dermatitis. Completed, enrolled 264 participants across 18 sites.
Detailed Summary
To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedNov 2013
Primary CompletionApr 2015
Study CompletionJun 2016
TodayJul 2026
First PostedNov 19, 2013
Enrollment StartNov 1, 2013
Primary CompletionApr 1, 2015
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.6 years ago
Interventions
nemolizumab (CIM331)drug
Placeboother